Phenelzine sulfate

Synonyms: 硫酸苯乙肼; 苯肼,硫酸盐
Phenelzine sulfate 是一种抗抑郁剂,也是一种不可逆的、具有口服活性的单胺氧化酶 (MAO-A 和 MAO-B) 抑制剂,可抑制 GABA 转氨酶和伯胺氧化酶 (PrAO)、螯合活性醛、抑制 LSD1 (Ki 5.6 μM) 以及氧化应激和脂肪生成,并可升高神经递质 (血清素、去甲肾上腺素、多巴胺) 水平,已被研究用于神经系统、代谢和癌症疾病,例如抑郁症和焦虑症、中风、脊髓损伤、创伤性脑损伤、多发性硬化症、帕金森病、阿尔茨海默病、炎症性疼痛、肥胖症和前列腺癌。
产品编号: MS-U48596 纯度: 99.95% CAS No.: 156-51-4 分子式: C8H14N2O4S 分子量: 234.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

Phenelzine sulfate 是一种抗抑郁剂,也是一种不可逆的、具有口服活性的单胺氧化酶 (MAO-A 和 MAO-B) 抑制剂,可抑制 GABA 转氨酶和伯胺氧化酶 (PrAO)、螯合活性醛、抑制 LSD1 (Ki 5.6 μM) 以及氧化应激和脂肪生成,并可升高神经递质 (血清素、去甲肾上腺素、多巴胺) 水平,已被研究用于神经系统、代谢和癌症疾病,例如抑郁症和焦虑症、中风、脊髓损伤、创伤性脑损伤、多发性硬化症、帕金森病、阿尔茨海默病、炎症性疼痛、肥胖症和前列腺癌。

生物实验数据

生物活性 Phenelzine sulfate is an antidepressant and an irreversible, orally active inhibitor of monoamine oxidase (MAO-A and MAO-B) that inhibits GABA transaminase and primary amine oxidase (PrAO), chelates reactive aldehydes, inhibits LSD1 (Ki 5.6 μM) as well as oxidative stress and adipogenesis, and elevates neurotransmitter (serotonin, norepinephrine, dopamine) levels, and has been studied for neurological, metabolic, and cancer diseases such as depression and anxiety, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson's disease, Alzheimer's disease, inflammatory pain, obesity, and prostate cancer.
体外研究
(In Vitro)

Phenelzine sulfate 可抑制重组小鼠 MAOA/MAOB、PIPOX、PCYOX1、ALDH2 和 SCRN3 蛋白。
Phenelzine (80 μM; 48 h; H460) sulfate 在 [3H] 胸苷掺入实验中,对 H460 细胞增殖的抑制率低于 50%。
Phenelzine (10-100 μM;24 小时;大鼠视网膜神经节细胞) sulfate 可减少 3-Aminopropanal 引起的毒性。
Phenelzine (150-300 nmol;30分钟;磷酸盐缓冲液) sulfate 可降低体外丙烯醛水平。

Cell Cytotoxicity Assay

Cell Line: Rat retinal ganglion cells
Concentration: 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: LDH release was measured 24 hours after cotreatment with 3-Aminopropanal, showing reduced toxicity.

Western Blot Analysis

Cell Line: LNCaP
Concentration: 3 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 48 h
Result: No significant changes in H3K4Me2 or total H3 levels were observed.

Cell Proliferation Assay

Cell Line: H460
Concentration: 80 μM
Incubation Time: 48 h
Result: Less than 50% reduction in 3H-thymidine incorporation.
体内研究
(In Vivo)

Phenelzine (31.6 mg/kg (0.028%);饮用;每日一次;12 周) sulfate 表现出比对照组更低的体脂含量、皮下白色脂肪组织 (WAT) 质量和骨骼肌脂质含量,且不降低体重增长或食物消耗。
Phenelzine (15 mg/kg;腹腔注射,损伤后 15 分钟) sulfate 可降低大鼠脊髓损伤 (SCI) 模型中的丙烯醛和 4-HNE 水平,并促进恢复。Phenelzine sulfate (水族箱水) 可通过降低氧化应激和维持多巴胺水平来减轻百草枯诱导的斑马鱼神经毒性,并促进斑马鱼脊髓损伤模型中的轴突再生和髓鞘再生。

Animal Model: Female C57BL/6 micEAE was induced in female C57/BL mice with MOG35-55 (MS-R86214)(subcutaneous injection).
Dosage: 15 mg/kg
Administration: IP; daily, for 28 days
Result: Reduced disease severity in the chronic phase and was associated with substantial improvements in exploratory behavior.
Showed a normalization of 5-HT levels in the ventral horn of the spinal cord that might account for the improvements in behavioral outcomes.
Animal Model: Rats; traumatic brain injury (TBI) model, induced by controlled cortical impact (CCI-TBI)
Dosage: 15 mg/kg
Administration: IP; once; 15 minutes post-injury
Result: Prevented the decrease in respiratory control ratio, increased cortical tissue sparing from 86 to 97%, and reduced 4-HNE levels in mitochondria.
Animal Model: Gerbils (male, 8 weeks); global ischemia model, induced by carotid ligation for 5 minutes followed by reperfusion
Dosage: 15 mg/kg, 30 mg/kg
Administration: IP; once daily; 6 days
Result: Significantly attenuated neuronal loss in the hippocampal CA1 region compared to ischemia-vehicle gerbils.
Animal Model: C57BL/6 mice (male, 9 weeks); no disease model
Dosage: 31.6 mg/kg
Administration: Drinking water; once daily; 12 weeks
Result: Exhibited lower body fat content, subcutaneous WAT mass and lipid content in skeletal muscles than control, without decreased body weight gain or food consumption. Phenelzine impaired the lipogenic but not the antilipolytic actions of insulin in WAT.
Lowered MAO activity and hydrogen peroxide release in WAT.
Decreased phosphoenolpyruvate carboxykinase (PEPCK) expression in subcutaneous WAT.
Animal Model: C57BL/6 mice (male, 9 weeks); no disease model
Dosage: 31.6 mg/kg
Administration: Drinking water; once daily; 12 weeks
Result: Lowered non-fasting blood glucose levels.
性状 固体
颜色 White to off-white

化学信息

分子量 234.27
分子式 C8H14N2O4S
CAS No. 156-51-4
别名 硫酸苯乙肼; 苯肼,硫酸盐

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (42.69 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (14.09 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (426.86 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.2686 mL21.3429 mL42.6858 mL106.7145 mL
5 mM0.8537 mL4.2686 mL8.5372 mL21.3429 mL
10 mM0.4269 mL2.1343 mL4.2686 mL10.6714 mL
15 mM0.2846 mL1.4229 mL2.8457 mL7.1143 mL
20 mM0.2134 mL1.0671 mL2.1343 mL5.3357 mL
25 mM0.1707 mL0.8537 mL1.7074 mL4.2686 mL
30 mM0.1423 mL0.7114 mL1.4229 mL3.5571 mL
40 mM0.1067 mL0.5336 mL1.0671 mL2.6679 mL
50 mM0.0854 mL0.4269 mL0.8537 mL2.1343 mL
60 mM0.0711 mL0.3557 mL0.7114 mL1.7786 mL
80 mM0.0534 mL0.2668 mL0.5336 mL1.3339 mL
100 mM0.0427 mL0.2134 mL0.4269 mL1.0671 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础